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ABSTRACT
Introduction: In most patients with type 2
diabetes mellitus (T2DM) and progressive beta-
cell insufficiency, insulin therapy is required to
achieve sufficient glycemic control. However,
insulin therapy may lead to weight gain and
increasing risk of hypoglycemia. Glucagon-like
peptide-1 receptor agonists are being used as add-
on therapy to insulin with favorable metabolic
effects. Nonetheless, to date only few studies exist
reporting on the combination of liraglutide and
insulin with a short follow-up period. The aim of
this study was to evaluate the efficacy and safety
of liraglutide as add-on to insulin in patients with
T2DM over a time period of up to 24–28 months.
Methods: Data of patients with T2DM, treated
with insulin and liraglutide at an outpatient
clinic in a tertiary referral hospital from
October 2009 until December 2011 were
retrospectively examined (n = 36). Glycated
hemoglobin (HbA1c), weight, total daily
insulin dose and side effects were assessed
5–8 months prior to liraglutide, at baseline
and at follow-up visits after 3, 6, 12–16 and
24–28 months.
Results: Median HbA1c decreased significantly
from 7.7% [interquartile range (IQR) 7.0–8.6] at
baseline to 6.8% (IQR 6.5–7.7, p = 0.001) at
3 months and 6.9% (IQR 6.3–7.6, p = 0.0001) at
6 months, but re-increased thereafter (at
24–28 months, median 7.5%, IQR 7.1–8.2,
p = 1.0). Median weight decreased significantly
from 99.8 kg (IQR 81–110) at baseline to 97.7 kg
(IQR 81.2–108.2, p = 0.027) at 3 months, but
rose again thereafter. Insulin dosage did not
change significantly over time. No severe
hypoglycemia or major side effects occurred.
Conclusions: In this observational study,
adding liraglutide to insulin in daily clinical
practice reduced HbA1c significantly within
6 months, but there may be a non-sustainable
effect during long-term treatment.
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INTRODUCTION
Lifestyle modification and oral antidiabetic
drugs are first line treatment measures in
patients with type 2 diabetes mellitus (T2DM).
Over time, progressive beta cell dysfunction
results in deteriorating glycemic control
requiring insulin therapy. However, insulin is
often associated with weight gain and increased
risk of hypoglycemia [1]. Together with the
need for (multiple) injections, insulin therapy
frequently meets reluctance in both patients
and physicians, and initiation of therapy is
often delayed [2]. Several trials showed that
Glucagon-like peptide-1 (GLP-1) receptor
agonists as monotherapy or in combination
with one or more oral antidiabetic agent have
beneficial metabolic effects leading to improved
glycemic control with a low risk of
hypoglycemia, and weight loss [3]. They are
now recommended as one of several two-drug
combination therapies, if metformin
monotherapy does not achieve/maintain the
defined glycated hemoglobin (HbA1c) target
over 3 months [4].
Several reports demonstrated favorable
effects of a combination therapy of a GLP-1
receptor agonist with insulin [5]. However, only
few studies included the use of liraglutide [6–
10], and follow-up time was short. Despite these
limited data, liraglutide is widely used (off-
label) as add-on therapy in patients on various
insulin regimens and oral antidiabetic drugs. In
2013, liraglutide was officially approved for use
in combination with basal insulin in Europe
(and the US). The aim of this observational
study was to retrospectively assess the efficacy
and safety of liraglutide as add-on therapy to
insulin in a daily clinical practice setting for a
duration up to 24–28 months.
METHODS
Eligible participants were adults (18–80 years)
with T2DM, BMI C 28 kg/m2 and HbA1c values
of 6.5–10% treated with metformin ± another
oral antidiabetic drug and insulin. Exclusion
criteria were pregnancy and intolerance for
liraglutide. The authors reviewed the charts of
all patients with T2DM with liraglutide being
added-on to insulin from October 2009 until
December 2011 at their outpatient clinic in a
tertiary referral hospital. Weight, body mass
index (BMI), HbA1c and insulin dose (units/
day, units/kg/day) were assessed 5–8 months
prior to liraglutide, at baseline, after 3, 6, 12–16
and 24–28 months.
Starting dose of liraglutide was 0.6 mg once
daily, with an increase to 1.2 mg after 2 weeks.
During the treatment period, no additional
antidiabetic drug was initiated. Oral drugs and
insulin dosage were individually reduced by the
attending physician according to current
glucose control. As the outpatient clinic is part
of a teaching hospital, all physicians followed
the same treatment strategies according to the
guidelines of the Swiss Society of Endocrinology
and Diabetes [11]. Hypoglycemic events were
assessed by patient interview and patients’
blood glucose meter readings were imported
into the DIABASS Pro Software, Mediaspects
GmbH, Konstanz, Germany. Severe
hypoglycemia was defined as an event
requiring assistance of another person to
actively administer carbohydrate, glucagon or
other resuscitative actions [12].
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
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(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
For statistical analysis linear mixed models
with random intercept were used to examine
changes in endpoints over time from baseline,
after 3, 6, 12–16 and 24–28 months. Such
regression models do not require complete
data (unlike in analysis of variance), so all
available data was analyzed [13]. All analysis
was performed in the R programming language
(version 3.0.1, R Core Team 2013 Center for
Statistics, Copenhagen, Denmark). The package
lme4 was used to estimate the mixed models,
while the multcomp [14] was used to compute
the p values and confidence intervals.
RESULTS
A total of 36 patients was on this combined
therapy regimen. After the baseline visit, four
patients preferred to be followed up by their
family physician and were therefore not
included in this follow-up. Three patients
stopped liraglutide due to exanthema at the
injection site, nausea and abdominal pain,
respectively. Among the remaining 29 patients,
median age was 59 years [interquartile range
(IQR) 53–67], disease duration 11 years (IQR
5–13), HbA1c 7.7% (IQR 7.0–8.6), weight
99.8 kg (IQR 81–110) and BMI 33.5 kg/m2 (IQR
29.4–37.6). At baseline, 17 were on basal insulin,
2 on prandial insulin and 10 on multiple insulin
injections. In addition, 24 patients were on
metformin, 12 on sulfonylureas, and 6 on
other oral antidiabetic agents.
Median HbA1c decreased significantly from
7.7% (IQR 7.0–8.6) at baseline to 6.8% (IQR
6.5–7.7, p = 0.001) at 3 months and 6.9%, (IQR
6.3–7.6, p = 0.0001) at 6 months, but re-
increased at 12–16 months (median 7.2%, IQR
6.7–7.9, p = 0.32) and 24–28 months (median
7.5%, IQR 7.1–8.2, p = 1.0). HbA1c prior to
intervention was lower (median 7.3%, IQR
7.1–7.9) than at baseline. Weight and BMI
decreased significantly from 99.8 kg and
33.5 kg/m2 (IQR 81–110 and 29.4–37.6)
respectively at baseline to 97.7 kg and 31.9 kg/
m2 (IQR 81.2–108.2 and 29.4–36), (p = 0.023
and 0.027) at 3 months. However weight and
BMI increased again after 6 months (median
97.5 kg and 31.5 kg/m2, IQR 84.5.5–111.5,
p = 0.16 and 29.4–35.1, p = 0.15), at
12–16 months (100.5 kg and 34.1 kg/m2, IQR
100.5–109.5, p = 0.17 and 30.7–36.7, p = 0.16)
and at 24–28 months (106.4 kg and 36.4 kg/m2,
IQR 96.9–118, p = 1.0 and 30.9–38.4, p = 1.0).
Insulin dosage did not change significantly over
time (Fig. 1). However, during follow-up, three
patients (10.3%) were able to completely stop
insulin therapy, and two patients (6.9%) could
simplify their multiple daily insulin injection
regimens to basal insulin at bedtime only.
Furthermore, sulfonylureas were stopped in 5
of 12 patients (41.7%) and all other antidiabetic
drugs beside metformin were stopped (e.g.
glitazones, glinides). No severe hypoglycemia
occurred over the entire period. Overall, 5
patients (15.6%) out of 32 followed-up
patients discontinued liraglutide due to side
effects. Three patients stopped liraglutide due to
exanthema at the injection site, nausea or
abdominal pain at the beginning and two
patients discontinued liraglutide due to
nausea/vomiting and pain at the injection site
after 3.5 and 12 months.
DISCUSSION
This retrospective study shows that liraglutide
as add-on therapy to insulin therapy decreases
HbA1c and weight during the first 6 months
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with a fading effect thereafter. No serious
hypoglycemic event occurred. The most
frequently reported side effects were nausea/
vomiting and pain/exanthema at the injection
site, leading to discontinuation of liraglutide in
15.6% of the patients.
The short-term findings on HbA1c and weight
reduction are in accordance with earlier
randomized and observational studies over
12 weeks on liraglutide added to insulin, which
found a reduction of HbA1c by 1.4–1.9% and
body weight by 5.1–5.6 kg, respectively [7, 8].
A recent report showed a decrease in HbA1c
levels of 0.77% and 4.5 kg weight reduction
over 26 weeks [10]. A most recent meta-analysis
of 15 studies on GLP-1 agonists in combination
with basal insulin with a maximum observation
time of 36 weeks (mean 24.8 weeks) yielded an
HbA1c reduction of 0.44% and weight loss of
3.22 kg [15]. The longest follow-up was in a
retrospective study until 38 weeks, where body
weight also re-increased in 20 patients on
liraglutide or exenatide in combination with
insulin [6], similar to the patient population in
the current study. Results with longer follow-up
time are only available in the reverse situation
of basal insulin added on to metformin and
liraglutide in a prospective study, showing
sustained HbA1c and weight reduction even
after 52 weeks [16].
Several reasons may account for the
unsustained effect of liraglutide on body
weight and HbA1c beyond 6 months in the
patients presented here. Firstly, reduction of
insulin dose or termination of oral antidiabetic
drugs may have led to the re-increase in HbA1c.
Secondly, no antidiabetic treatment has been
shown to prevent deterioration of b-cell
function, which drives the natural history of
the disease [1]. Thirdly, the authors often
observe that patient adherence, especially
regarding dietary restrictions, fades after a few
months of starting liraglutide, which may be
explained by the disappearing gastrointestinal
side effects. Subjects willing to participate in a
prospective study are supposedly more
motivated and adherent to improve their
glycemic control in general. Finally, subjects
early achieving adequate glycemic control
within a few weeks or months usually return
to their referring physicians, whereas the more
challenging patients remained in the tertiary
clinic and were eligible for this study. The
clinical setting reflects a real world situation
and shows the difficulties which diabetologists
face in their daily work.
In contrast to other studies with GLP-1
receptor agonists and insulin [17], there was
no statistically significant reduction in daily
insulin dose in the present study. However, a
remarkable proportion of the patients either
completely ceased insulin or at least were able
to omit prandial insulin injections. Moreover,
in many of the patients, oral antidiabetic drugs
(beside metformin) could be stopped, which is
especially beneficial for patients with
sulfonylureas bearing an increased risk of
hypoglycemia.
In accordance with earlier reports, liraglutide
was well tolerated. Remarkably, no events of
severe hypoglycemia were observed in the
present cohort. The dropout rate of 15.6% due
to side effects was comparable to other reports
[18, 19].
Limitations of this study are the small
patient number and potentially heterogeneous
patient characteristics, including patients
with long-standing diabetes as well as the
Fig. 1 Course of glycated hemoglobin (HbA1c), insulin
(total units and units per kg body weight), weight and
body mass index (BMI) prior (T-1), at baseline (T0) and
during follow-up after 3 (T1), 6 (T2), 12–16 (T3) and
24–28 months (T4)
b
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retrospective study design. As this was an
observational study, there was no control
group. The fact that HbA1c was increasing
before baseline may point to a regression
towards the mean. The setting reflects the real
life situation in an outpatient clinic of a tertiary
referral hospital covering around 500,000
inhabitants. During the observational period,
combination therapy of liraglutide and insulin
was not yet approved by Swissmedic (Swiss
agency for the authorisation and supervision
of therapeutic products), which explains the
small number of patients. However, a major
strength of this study is the long observational
period of up to 24–28 months, as compared to
most earlier studies with a follow-up time of
usually 24 weeks with a few lasting up to
38 weeks. In the meantime, add-on therapy of
liraglutide to basal insulin was approved due to
its unequivocal positive effect. The
combination of liraglutide with multiple
insulin injections, however, is still awaiting
approval.
CONCLUSION
Adding liraglutide to pre-existing insulin
therapy in T2DM reduces HbA1c and body
weight significantly during the initial
6 months of treatment, but there may be a
non-sustainable effect during long-term
treatment.
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